List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 382 studies with search of: Peginterferon alfa-2 OR "Pegasys (2a) OR PEG-Intron (2b)"[TREATMENT] AND HIV [CONDITION]
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Recruiting Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B
Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir and peginterferon alfa-2a;   Drug: Placebo and peginterferon
2 Recruiting Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B
Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir and peginterferon (Pegasys) (52 weeks);   Drug: Peginterferon (Pegasys) (96 weeks);   Drug: Peginterferon (Pegasys) (48 weeks)
3 Completed Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV
Condition: HIV Infections
Interventions: Drug: Peginterferon alfa-2a, Ribavirin, epoetin-β;   Drug: Peginterferon alfa-2a + Ribavirin for 12 weeks
4 Active, not recruiting Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Patients With Acute Hepatitis C (Study P03552)
Condition: Hepatitis C
Interventions: Biological: Peginterferon alfa-2b;   Drug: Ribavirin
5 Active, not recruiting Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
Condition: Hepatitis C
Interventions: Drug: MP-424;   Drug: Ribavirin;   Drug: Peginterferon Alfa-2b
6 Terminated Efficacy and Safety of Telbivudine in Treatment naïve Patients With HBeAg-positive Chronic Hepatitis B (CHB)
Condition: Hepatitis B
Intervention: Drug: Telbivudine, peginterferon alpha-2a
7 Active, not recruiting A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
Conditions: Liver Cirrhosis;   Chronic Hepatitis C
Interventions: Drug: peginterferon alfa-2a 180μg;   Drug: peginterferon alfa-2a 90μg;   Drug: ribavirin
8 Terminated Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders
Condition: Hepatitis C, Chronic
Interventions: Drug: peg-interferon alfa-2b;   Drug: ribavirin;   Drug: amantadine
9 Completed REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a (40KD) [PEGASYS];   Drug: Ribavirin
10 Active, not recruiting Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM1)
Condition: Hepatitis C, Chronic
Interventions: Drug: Boceprevir;   Other: Placebo;   Biological: Peginterferon alfa-2a;   Drug: Ribavirin
11 Recruiting PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: PEG-interferon alfa-2b;   Drug: sorafenib tosylate;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis
12 Recruiting Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C
Conditions: Hepatitis B, Chronic;   Hepatitis C, Chronic
Intervention: Drug: Peginterferon Alfa-2a plus Ribavirin
13 Completed A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: peginterferon alfa-2a;   Drug: rivavirin
14 Completed Interferon Gamma With Peg-Interferon Alpha 2a and Ribavirin in Non Responders Patients With Chronic Hepatitis C
Condition: Hepatitis C, Chronic
Interventions: Drug: Peg-interferon alpha 2a (drug);   Drug: Ribavirin (drug);   Drug: Interferon gamma (drug)
15 Active, not recruiting Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C
Condition: Chronic Hepatitis C
Interventions: Drug: Nitazoxanide;   Drug: Placebo;   Biological: Peginterferon alfa-2a;   Drug: Ribavirin
16 Enrolling by invitation Three-year Follow-up of Subjects After Administration of Boceprevir for the Treatment of Chronic Hepatitis C (Study P05063)
Conditions: Hepatitis C, Chronic;   Hepacivirus
Interventions: Drug: Boceprevir (SCH 503034);   Biological: Peginterferon alfa-2b (SCH 054031);   Drug: Ribavirin (SCH 018908);   Drug: Placebo
17 Recruiting PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR)
Condition: Chronic Hepatitis C
Intervention: Drug: Peginterferon alfa-2a and Ribavirin
18 Recruiting Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load
Condition: Chronic Hepatitis B
Intervention: Drug: Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
19 Completed Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
Conditions: Hepatitis C;   Hemophilia
Intervention: Drug: PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
20 Completed Peginterferon Alpha-2a Maintenance Therapy for Portal Hypertension in Patients With Hepatitis C
Conditions: Hepatitis C;   Cirrhosis;   Fibrosis
Intervention: Drug: Peginterferon Alpha-2a

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services